Does the media favor LEGN or WVE?

In the previous week, WAVE Life Sciences had 2 more articles in the media than Legend Biotech. MarketBeat recorded 17 mentions for WAVE Life Sciences and 15 mentions for Legend Biotech. Legend Biotech's average media sentiment score of 0.34 beat WAVE Life Sciences' score of -0.19 indicating that Legend Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 5 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral WAVE Life Sciences 3 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to WVE or ACAD?

In the previous week, WAVE Life Sciences had 3 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 17 mentions for WAVE Life Sciences and 14 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 1.18 beat WAVE Life Sciences' score of -0.19 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment WAVE Life Sciences 3 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral ACADIA Pharmaceuticals 11 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer WVE or EWTX?

In the previous week, WAVE Life Sciences had 11 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 17 mentions for WAVE Life Sciences and 6 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.24 beat WAVE Life Sciences' score of -0.19 indicating that Edgewise Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment WAVE Life Sciences 3 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Edgewise Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VKTX or WVE?

In the previous week, Viking Therapeutics had 20 more articles in the media than WAVE Life Sciences. MarketBeat recorded 37 mentions for Viking Therapeutics and 17 mentions for WAVE Life Sciences. Viking Therapeutics' average media sentiment score of 0.63 beat WAVE Life Sciences' score of -0.19 indicating that Viking Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 14 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 6 Negative mention(s) 0 Very Negative mention(s) Positive WAVE Life Sciences 3 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor TNGX or WVE?

In the previous week, WAVE Life Sciences had 9 more articles in the media than Tango Therapeutics. MarketBeat recorded 17 mentions for WAVE Life Sciences and 8 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 1.41 beat WAVE Life Sciences' score of -0.19 indicating that Tango Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive WAVE Life Sciences 3 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral

WAVE Life Sciences (WVE) Competitors

$5.51 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$5.56 +0.06 (+1.00%)

As of 07/31/2026 07:34 PM Eastern

Compare

WVE vs. LEGN, ACAD, EWTX, VKTX, and TNGX

Should you buy WAVE Life Sciences stock or one of its competitors? MarketBeat compares WAVE Life Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with WAVE Life Sciences include Legend Biotech (LEGN), ACADIA Pharmaceuticals (ACAD), Edgewise Therapeutics (EWTX), Viking Therapeutics (VKTX), and Tango Therapeutics (TNGX).

How does WAVE Life Sciences compare to Legend Biotech?

Legend Biotech (NASDAQ:LEGN) and WAVE Life Sciences (NASDAQ:WVE) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

In the previous week, WAVE Life Sciences had 2 more articles in the media than Legend Biotech. MarketBeat recorded 17 mentions for WAVE Life Sciences and 15 mentions for Legend Biotech. Legend Biotech's average media sentiment score of 0.34 beat WAVE Life Sciences' score of -0.19 indicating that Legend Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Legend Biotech	5 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
WAVE Life Sciences	3 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

Legend Biotech has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.26, meaning that its stock price is 226% less volatile than the broader market.

Legend Biotech has a net margin of -21.98% compared to WAVE Life Sciences' net margin of -309.73%. Legend Biotech's return on equity of -24.92% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-21.98%	-24.92%	-14.87%
WAVE Life Sciences	-309.73%	-50.36%	-40.06%

Legend Biotech currently has a consensus price target of $55.29, suggesting a potential upside of 198.04%. WAVE Life Sciences has a consensus price target of $23.88, suggesting a potential upside of 333.44%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe WAVE Life Sciences is more favorable than Legend Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.53
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94

WAVE Life Sciences has lower revenue, but higher earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.14B	3.03	-$296.80M	-$0.68	N/A
WAVE Life Sciences	$42.73M	25.41	-$204.38M	-$1.09	N/A

70.9% of Legend Biotech shares are held by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are held by institutional investors. 0.0% of Legend Biotech shares are held by company insiders. Comparatively, 24.3% of WAVE Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

WAVE Life Sciences beats Legend Biotech on 10 of the 17 factors compared between the two stocks.

How does WAVE Life Sciences compare to ACADIA Pharmaceuticals?

WAVE Life Sciences (NASDAQ:WVE) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, media sentiment, dividends, analyst recommendations and risk.

WAVE Life Sciences currently has a consensus target price of $23.88, indicating a potential upside of 333.44%. ACADIA Pharmaceuticals has a consensus target price of $32.31, indicating a potential upside of 24.88%. Given WAVE Life Sciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe WAVE Life Sciences is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94
ACADIA Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, WAVE Life Sciences had 3 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 17 mentions for WAVE Life Sciences and 14 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 1.18 beat WAVE Life Sciences' score of -0.19 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
WAVE Life Sciences	3 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
ACADIA Pharmaceuticals	11 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ACADIA Pharmaceuticals has higher revenue and earnings than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
WAVE Life Sciences	$42.73M	25.41	-$204.38M	-$1.09	N/A
ACADIA Pharmaceuticals	$1.07B	4.13	$391M	$2.20	11.76

WAVE Life Sciences has a beta of -1.26, suggesting that its share price is 226% less volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market.

ACADIA Pharmaceuticals has a net margin of 34.30% compared to WAVE Life Sciences' net margin of -309.73%. ACADIA Pharmaceuticals' return on equity of 9.61% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
WAVE Life Sciences	-309.73%	-50.36%	-40.06%
ACADIA Pharmaceuticals	34.30%	9.61%	7.07%

89.7% of WAVE Life Sciences shares are held by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 24.3% of WAVE Life Sciences shares are held by company insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

ACADIA Pharmaceuticals beats WAVE Life Sciences on 11 of the 17 factors compared between the two stocks.

How does WAVE Life Sciences compare to Edgewise Therapeutics?

WAVE Life Sciences (NASDAQ:WVE) and Edgewise Therapeutics (NASDAQ:EWTX) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

Edgewise Therapeutics has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -309.73%. Edgewise Therapeutics' return on equity of -32.55% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
WAVE Life Sciences	-309.73%	-50.36%	-40.06%
Edgewise Therapeutics	N/A	-32.55%	-31.04%

WAVE Life Sciences presently has a consensus target price of $23.88, indicating a potential upside of 333.44%. Edgewise Therapeutics has a consensus target price of $48.75, indicating a potential upside of 26.85%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, equities analysts plainly believe WAVE Life Sciences is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

WAVE Life Sciences has a beta of -1.26, indicating that its share price is 226% less volatile than the broader market. Comparatively, Edgewise Therapeutics has a beta of 0.3, indicating that its share price is 70% less volatile than the broader market.

In the previous week, WAVE Life Sciences had 11 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 17 mentions for WAVE Life Sciences and 6 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.24 beat WAVE Life Sciences' score of -0.19 indicating that Edgewise Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
WAVE Life Sciences	3 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
Edgewise Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

89.7% of WAVE Life Sciences shares are owned by institutional investors. 24.3% of WAVE Life Sciences shares are owned by insiders. Comparatively, 21.3% of Edgewise Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Edgewise Therapeutics has lower revenue, but higher earnings than WAVE Life Sciences. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
WAVE Life Sciences	$42.73M	25.41	-$204.38M	-$1.09	N/A
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.66	N/A

Summary

WAVE Life Sciences beats Edgewise Therapeutics on 9 of the 15 factors compared between the two stocks.

How does WAVE Life Sciences compare to Viking Therapeutics?

Viking Therapeutics (NASDAQ:VKTX) and WAVE Life Sciences (NASDAQ:WVE) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment.

Viking Therapeutics currently has a consensus price target of $97.88, suggesting a potential upside of 208.36%. WAVE Life Sciences has a consensus price target of $23.88, suggesting a potential upside of 333.44%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe WAVE Life Sciences is more favorable than Viking Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.67
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94

76.0% of Viking Therapeutics shares are held by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are held by institutional investors. 5.3% of Viking Therapeutics shares are held by insiders. Comparatively, 24.3% of WAVE Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Viking Therapeutics has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -309.73%. WAVE Life Sciences' return on equity of -50.36% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-94.56%	-82.75%
WAVE Life Sciences	-309.73%	-50.36%	-40.06%

In the previous week, Viking Therapeutics had 20 more articles in the media than WAVE Life Sciences. MarketBeat recorded 37 mentions for Viking Therapeutics and 17 mentions for WAVE Life Sciences. Viking Therapeutics' average media sentiment score of 0.63 beat WAVE Life Sciences' score of -0.19 indicating that Viking Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	14 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Positive
WAVE Life Sciences	3 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

WAVE Life Sciences has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A
WAVE Life Sciences	$42.73M	25.41	-$204.38M	-$1.09	N/A

Viking Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.26, meaning that its stock price is 226% less volatile than the broader market.

Summary

WAVE Life Sciences beats Viking Therapeutics on 11 of the 15 factors compared between the two stocks.

How does WAVE Life Sciences compare to Tango Therapeutics?

Tango Therapeutics (NASDAQ:TNGX) and WAVE Life Sciences (NASDAQ:WVE) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.

Tango Therapeutics has higher revenue and earnings than WAVE Life Sciences. Tango Therapeutics is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	63.03	-$101.59M	-$0.83	N/A
WAVE Life Sciences	$42.73M	25.41	-$204.38M	-$1.09	N/A

79.0% of Tango Therapeutics shares are owned by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are owned by institutional investors. 6.5% of Tango Therapeutics shares are owned by insiders. Comparatively, 24.3% of WAVE Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Tango Therapeutics has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -309.73%. Tango Therapeutics' return on equity of -41.54% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	N/A	-41.54%	-33.44%
WAVE Life Sciences	-309.73%	-50.36%	-40.06%

In the previous week, WAVE Life Sciences had 9 more articles in the media than Tango Therapeutics. MarketBeat recorded 17 mentions for WAVE Life Sciences and 8 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 1.41 beat WAVE Life Sciences' score of -0.19 indicating that Tango Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
WAVE Life Sciences	3 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

Tango Therapeutics currently has a consensus price target of $42.15, indicating a potential upside of 55.09%. WAVE Life Sciences has a consensus price target of $23.88, indicating a potential upside of 333.44%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe WAVE Life Sciences is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94

Tango Therapeutics has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.26, suggesting that its stock price is 226% less volatile than the broader market.

Summary

Tango Therapeutics beats WAVE Life Sciences on 9 of the 17 factors compared between the two stocks.

Get WAVE Life Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WVE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

WVE vs. The Competition

Export

Metric	WAVE Life Sciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.09B	$3.54B	$6.85B	$12.42B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-5.06	7.38	282.30	24.66
Price / Sales	25.41	1,200.34	563.12	75.93
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	1.78	16.96	10.96	6.07
Net Income	-$204.38M	-$12.56M	$3.49B	$347.99M
7 Day Performance	-6.93%	-1.77%	-0.64%	-0.44%
1 Month Performance	-11.98%	-8.39%	-5.23%	-4.81%
1 Year Performance	-36.15%	48.40%	61.97%	18.61%

WAVE Life Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
WVE WAVE Life Sciences	3.0384 of 5 stars	$5.51 flat	$23.88 +333.4%	-36.2%	$1.09B	$42.73M	N/A	240	Trending News Earnings Report Analyst Forecast Gap Up
LEGN Legend Biotech	3.0922 of 5 stars	$22.22 -5.6%	$55.38 +149.3%	-52.2%	$4.37B	$1.03B	N/A	2,965
ACAD ACADIA Pharmaceuticals	4.5185 of 5 stars	$24.84 +0.0%	$33.17 +33.5%	+9.9%	$4.25B	$1.07B	11.29	510	Positive News Upcoming Earnings Insider Trade Gap Up
EWTX Edgewise Therapeutics	3.5016 of 5 stars	$40.84 +3.9%	$48.75 +19.4%	+168.6%	$4.23B	N/A	N/A	60	Positive News Upcoming Earnings
VKTX Viking Therapeutics	3.3756 of 5 stars	$34.79 -1.7%	$97.00 +178.8%	-2.9%	$4.11B	N/A	N/A	20	Trending News Earnings Report Analyst Revision Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:WVE) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

WAVE Life Sciences (WVE) Competitors

WVE vs. LEGN, ACAD, EWTX, VKTX, and TNGX

How does WAVE Life Sciences compare to Legend Biotech?

Summary

How does WAVE Life Sciences compare to ACADIA Pharmaceuticals?

Summary

How does WAVE Life Sciences compare to Edgewise Therapeutics?

Summary

How does WAVE Life Sciences compare to Viking Therapeutics?

Summary

How does WAVE Life Sciences compare to Tango Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WVE vs. The Competition

WAVE Life Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

WAVE Life Sciences (WVE) Competitors

WVE vs. LEGN, ACAD, EWTX, VKTX, and TNGX

How does WAVE Life Sciences compare to Legend Biotech?

Does the media favor LEGN or WVE?

Which has more volatility and risk, LEGN or WVE?

Is LEGN or WVE more profitable?

Do analysts rate LEGN or WVE?

Which has preferable earnings & valuation, LEGN or WVE?

Do institutionals & insiders hold more shares of LEGN or WVE?

Summary

How does WAVE Life Sciences compare to ACADIA Pharmaceuticals?

Do analysts rate WVE or ACAD?

Does the media refer more to WVE or ACAD?

Which has stronger valuation & earnings, WVE or ACAD?

Which has more volatility & risk, WVE or ACAD?

Is WVE or ACAD more profitable?

Do institutionals and insiders believe in WVE or ACAD?

Summary

How does WAVE Life Sciences compare to Edgewise Therapeutics?

Is WVE or EWTX more profitable?

Do analysts prefer WVE or EWTX?

Which has more risk and volatility, WVE or EWTX?

Does the media prefer WVE or EWTX?

Do institutionals and insiders believe in WVE or EWTX?

Which has better valuation & earnings, WVE or EWTX?

Summary

How does WAVE Life Sciences compare to Viking Therapeutics?

Do analysts recommend VKTX or WVE?

Do insiders and institutionals have more ownership in VKTX or WVE?

Is VKTX or WVE more profitable?

Does the media prefer VKTX or WVE?

Which has better earnings & valuation, VKTX or WVE?

Which has more risk and volatility, VKTX or WVE?

Summary

How does WAVE Life Sciences compare to Tango Therapeutics?

Which has higher earnings and valuation, TNGX or WVE?

Do institutionals & insiders hold more shares of TNGX or WVE?

Is TNGX or WVE more profitable?

Does the media favor TNGX or WVE?

Do analysts rate TNGX or WVE?

Which has more risk & volatility, TNGX or WVE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WVE vs. The Competition

WAVE Life Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools